These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 33443552)

  • 21. [Development of novel cereblon modulators and their target molecules].
    Ito T
    Rinsho Ketsueki; 2022; 63(6):573-579. PubMed ID: 35831190
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficient Synthesis of Immunomodulatory Drug Analogues Enables Exploration of Structure-Degradation Relationships.
    Burslem GM; Ottis P; Jaime-Figueroa S; Morgan A; Cromm PM; Toure M; Crews CM
    ChemMedChem; 2018 Aug; 13(15):1508-1512. PubMed ID: 29870139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rapid Progress in the Use of Immunomodulatory Drugs and Cereblon E3 Ligase Modulators in the Treatment of Multiple Myeloma.
    Charliński G; Vesole DH; Jurczyszyn A
    Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572892
    [TBL] [Abstract][Full Text] [Related]  

  • 24. ARID2 is a pomalidomide-dependent CRL4
    Yamamoto J; Suwa T; Murase Y; Tateno S; Mizutome H; Asatsuma-Okumura T; Shimizu N; Kishi T; Momose S; Kizaki M; Ito T; Yamaguchi Y; Handa H
    Nat Chem Biol; 2020 Nov; 16(11):1208-1217. PubMed ID: 32958952
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.).
    Gandhi AK; Kang J; Havens CG; Conklin T; Ning Y; Wu L; Ito T; Ando H; Waldman MF; Thakurta A; Klippel A; Handa H; Daniel TO; Schafer PH; Chopra R
    Br J Haematol; 2014 Mar; 164(6):811-21. PubMed ID: 24328678
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Discovery of the target for immunomodulatory drugs (IMiDs)].
    Ito T; Ando H; Handa H
    Rinsho Ketsueki; 2016 May; 57(5):556-62. PubMed ID: 27263779
    [TBL] [Abstract][Full Text] [Related]  

  • 27. High levels of CRBN isoform lacking IMiDs binding domain predicts for a worse response to IMiDs-based upfront therapy in newly diagnosed myeloma patients.
    Borsi E; Mazzocchetti G; Dico AF; Vigliotta I; Martello M; Poletti A; Solli V; Armuzzi S; Taurisano B; Kanapari A; Pistis I; Zamagni E; Tacchetti P; Pantani L; Mancuso K; Rocchi S; Rizzello I; Cavo M; Terragna C
    Clin Exp Med; 2023 Dec; 23(8):5227-5239. PubMed ID: 37815734
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genome-wide CRISPR screens reveal genetic mediators of cereblon modulator toxicity in primary effusion lymphoma.
    Patil A; Manzano M; Gottwein E
    Blood Adv; 2019 Jul; 3(14):2105-2117. PubMed ID: 31300418
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cereblon as a primary target of IMiDs].
    Ito T; Handa H
    Rinsho Ketsueki; 2019; 60(9):1013-1019. PubMed ID: 31597822
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Immunomodulatory drugs (IMiDs)].
    Oshima K; Ichinohe T
    Nihon Rinsho; 2014 Jun; 72(6):1130-5. PubMed ID: 25016816
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cereblon (
    Iskierka-Jażdżewska E; Canzian F; Stępień A; Martino A; Campa D; Stein A; Krawczyk-Kuliś M; Rybicka-Ramos M; Kyrcz-Krzemień S; Butrym A; Mazur G; Jurczyszyn A; Zawirska D; Grząśko N; Tomczak W; Subocz E; Wątek M; Pasiarski M; Rymko M; Całbecka M; Druzd-Sitek A; Walewski J; Kruszewski M; Raźny M; Zaucha JM; Dudziński M; Gaj P; Robak T; Warzocha K; Jamroziak K
    Leuk Lymphoma; 2020 Mar; 61(3):699-706. PubMed ID: 31746254
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PLZF and its fusion proteins are pomalidomide-dependent CRBN neosubstrates.
    Shimizu N; Asatsuma-Okumura T; Yamamoto J; Yamaguchi Y; Handa H; Ito T
    Commun Biol; 2021 Nov; 4(1):1277. PubMed ID: 34764413
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Thalidomide Inhibits Human iPSC Mesendoderm Differentiation by Modulating CRBN-dependent Degradation of SALL4.
    Belair DG; Lu G; Waller LE; Gustin JA; Collins ND; Kolaja KL
    Sci Rep; 2020 Feb; 10(1):2864. PubMed ID: 32071327
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Ubiquitination-Dependent and -Independent Functions of Cereblon in Cancer and Neurological Diseases.
    Zhou L; Xu G
    J Mol Biol; 2022 Mar; 434(5):167457. PubMed ID: 35045330
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A genome-scale CRISPR-Cas9 screening in myeloma cells identifies regulators of immunomodulatory drug sensitivity.
    Liu J; Song T; Zhou W; Xing L; Wang S; Ho M; Peng Z; Tai YT; Hideshima T; Anderson KC; Cang Y
    Leukemia; 2019 Jan; 33(1):171-180. PubMed ID: 30026574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Protein degraders - from thalidomide to new PROTACs.
    Ito T
    J Biochem; 2024 Apr; 175(5):507-519. PubMed ID: 38140952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identification of lenalidomide resistance pathways in myeloma and targeted resensitization using cereblon replacement, inhibition of STAT3 or targeting of IRF4.
    Zhu YX; Shi CX; Bruins LA; Wang X; Riggs DL; Porter B; Ahmann JM; de Campos CB; Braggio E; Bergsagel PL; Stewart AK
    Blood Cancer J; 2019 Feb; 9(2):19. PubMed ID: 30741931
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Homo-PROTACs for the Chemical Knockdown of Cereblon.
    Steinebach C; Lindner S; Udeshi ND; Mani DC; Kehm H; Köpff S; Carr SA; Gütschow M; Krönke J
    ACS Chem Biol; 2018 Sep; 13(9):2771-2782. PubMed ID: 30118587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance.
    Broyl A; Kuiper R; van Duin M; van der Holt B; el Jarari L; Bertsch U; Zweegman S; Buijs A; Hose D; Lokhorst HM; Goldschmidt H; Sonneveld P; ;
    Blood; 2013 Jan; 121(4):624-7. PubMed ID: 23233657
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genome-wide screening reveals a role for subcellular localization of CRBN in the anti-myeloma activity of pomalidomide.
    Tateno S; Iida M; Fujii S; Suwa T; Katayama M; Tokuyama H; Yamamoto J; Ito T; Sakamoto S; Handa H; Yamaguchi Y
    Sci Rep; 2020 Mar; 10(1):4012. PubMed ID: 32132601
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.